

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **Zylox-Tonbridge Medical Technology Co., Ltd.**

### **歸創通橋醫療科技股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 2190)**

## **VOLUNTARY ANNOUNCEMENT NATIONAL MEDICAL PRODUCTS ADMINISTRATION GRANTED MARKETING APPROVAL FOR ZENFLOW®T18 PERIPHERAL BALLOON CATHETER**

This announcement is made by Zylox-Tonbridge Medical Technology Co., Ltd. (the “**Company**”, together with its subsidiary, the “**Group**”) on a voluntary basis to provide the shareholders of the Company and potential investors with updated information in relation to the latest business and new product development of the Group.

The Company is pleased to announce that the ZENFLOW®T18 Peripheral Balloon Catheter (“**ZENFLOW®T18**”), self-developed by the Group, has been recently granted official marketing approval. As of the date of this announcement, the Company has obtained approvals from the National Medical Products Administration for a total of 32 products in the People’s Republic of China.

ZENFLOW®T18 is a tapered percutaneous transluminal angioplasty (“**PTA**”) balloon catheter, which is suitable for the peripheral vascular system (including the iliac artery, femoral artery, iliofemoral artery, popliteal artery and infrapopliteal artery). The balloon catheter is designed with a thin head end and a slightly thicker tail end, forming a tapered structure. The tapered structure can better adapt to changes in vascular taper, reduce excessive expansion of and damage to the vessel wall, minimize the incidence of entrapment, and improve the therapeutic effect in the lower extremity arteries, while providing the basis for vascular preparation for drug coated PTA balloon catheter (DCB) treatment. The maximum balloon length is 300mm, which can meet the needs of the lower extremity arteries. At the same time, ZENFLOW®T18 inherits the outstanding ZENFLOW®PTA balloon catheter platform technology. The non-invasive tapered head end fits guidewire to protect the vessels, with clear platinum-iridium visualization and ultra-smooth hydrophilic coating for good pass-through and delivery.

By order of the board  
**Zylox-Tonbridge Medical Technology Co., Ltd.**  
**Dr. Jonathon Zhong Zhao**  
*Chairman and Executive Director*

Hong Kong, December 11, 2023

*As of the date of this announcement, the board of directors of the Company comprises Dr. Jonathon Zhong Zhao, Mr. Yang Xie and Dr. Zheng Li as executive directors, Mr. Stephen Hui Wang, Dr. Steven Dasong Wang and Mr. Dongfang Li as non-executive directors, and Dr. Jian Ji, Mr. Hongze Liang and Ms. Yun Qiu as independent non-executive directors.*